Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
10 healthy volunteers will be enrolled to each receive two subcutaneous injections of ISIS
113715 in the abdomen on Study Day 1. Each subject will receive their two injections within a
5-minute period. On Study Days 2 and 8, each subject's injection sites will be assessed for
dermatologic effects. The Isis Project Physician(s) will observe the injection sites on Study
Day 2 and may also observe on Study Day 8.
Routine clinical chemistry, hematology, and urinalysis tests will be performed on Study Day 1
and Day 8. Subjects will be contacted by telephone on Study Day 30 to monitor for the
occurrence of new serious adverse events (SAEs). Thereafter, the subjects will be discharged
from the study.